Date: 2011-07-26
Type of information: Licensing agreement
Compound: POTELLIGENT® Technology
Company: arGEN-X (The Netherlands – Belgium) BioWa (Japan)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details: arGEN-X has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology. Under this license agreement, arGEN-X will apply POTELLIGENT® Technology to its own novel mAbs addressing cancer and inflammatory disorders and will offer antibodies encompassing both technologies to its commercial partners. By combining the power of the SIMPLE Antibody™ platform with POTELLIGENT® Technology, arGEN-X expects to increase the intrinsic potency of these mAbs even further. arGEN-X’s SIMPLE Antibody™ platform is unique in providing human variable regions of unprecedented diversity, allowing the rapid selection of antibodies with superb functional potency. In under two years, these attributes have already been validated preclinically in seven in vivo and ex vivo models, highlighting the productivity of the technology.
Financial terms:
Latest news:
